Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis

Hepatology Research

Volumn 46, Issue 12, 2016, Pages 1194-1202

  Nishikawa, Hiroki ^a   Enomoto, Hirayuki ^a   Iwata, Yoshinori ^a   Kishino, Kyohei ^a   Shimono, Yoshihiro ^a   Hasegawa, Kunihiro ^a   Nakano, Chikage ^a   Takata, Ryo ^a   Yoh, Kazunori ^a   Nishimura, Takashi ^a   Aizawa, Nobuhiro ^a   Sakai, Yoshiyuki ^a   Ikeda, Naoto ^a   Takashima, Tomoyuki ^a   Ishii, Akio ^a   Iijima, Hiroko ^a   Nakamura, Hideji ^b   Nishiguchi, Shuhei ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Nissay Hospital   (Japan)

Author keywords

liver fibrosis; non alcoholic steatohepatitis; predictability; serum marker; Wisteria floribunda agglutinin positive Mac 2 binding protein

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ POSITIVE MAC 2 BINDING PROTEIN;

ACCURACY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 84962551528     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12662     Document Type: Article

References (31)

1. Tokushige K, Hashimoto E, Horie Y et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011; 46: 1230–7.
2. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012; 32: 30–8.
3. Argo CK, Northup PG, Al-Osaimi AM et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51(2): 371–9.
4. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46(Suppl 1): 63–9.
5. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51(5): 1820–32.
6. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40(Suppl 1): S5–10.
7. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–38.
8. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.
9. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042–7.
10. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40(Suppl 1): S11–6.
11. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195–203.
12. Enomoto H, Bando Y, Nakamura H et al. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(24): 7427–35.
13. Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol 2013; 43(5): 1333–42.
14. Fujiyoshi M, Kuno A, Gotoh M et al. Hepatitis Glyco-biomarker Study Group. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015; Nov; 50(11): 1134–44.
15. Toshima T, Shirabe K, Ikegami T et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50(1): 76–84.
16. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60(5): 1563–70.
17. Tamaki N, Kurosaki M, Kuno A et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015; Oct; 45(10): E 82–8.
18. Hanai T, Shiraki M, Ohnishi S et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015; Nov; 45(11): 1083–90.
19. Kuno A, Ikehara Y, Tanaka Y et al. A serum “sweet-doughnut” 272 protein facilitates fibrosis evaluation and therapy assessment in patients 273 with viral hepatitis. Sci Rep 2013; 3: 1065.
20. Kuno A, Sato T, Shimazaki H et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013; 7(9–10): 642–7.
21. Umemura T, Joshita S, Sekiguchi T et al. Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. Am J Gastroenterol 2015; 110(6): 857–64.
22. Sasaki R, Yamasaki K, Abiru S et al. Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLoS One 2015; 10(6) e0129053.
23. Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2014; Jul; 50(7): 776–84.
24. Watanabe S, Hashimoto E, Ikejima K et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 2015; 45(4): 363–77.
25. Kleiner DE, Brunt EM, Van Natta M et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6): 1313–21.
26. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467–74.
27. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38(2): 518–26.
28. Sterling RK, Lissen E, Clumeck N et al. APRICOT Clinical nvestigators: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43(6): 1317–25.
29. Kamada Y, Akita M, Takeda Y et al. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One 2013; 8(6) e66328.
30. Kamada Y, Ono M, Hyogo H, et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology 2015; 62(5): 1433–43.
31. Nishikawa H, Enomoto H, Iwata Y et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res 2015; Sep 25. doi:10.1111/hepr.12596.